Welcome to our dedicated page for MESA LABORATORIES /CO/ SEC filings (Ticker: MLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MESA LABORATORIES /CO/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MESA LABORATORIES /CO/'s regulatory disclosures and financial reporting.
Mesa Laboratories Inc. executive Lyndsey Elizabeth Crennen, Chief Accounting Officer, has filed an initial statement of ownership showing her equity stake in the company. The filing lists existing holdings and does not report new open‑market trades.
She directly holds 1,863 shares of Common Stock. In addition, she holds several non‑qualified stock option awards, including options over 369 shares at an exercise price of $268.85 per share expiring on September 1, 2027, 488 shares at $185.57 expiring on June 15, 2028, and 646 shares at $131.67 expiring on June 21, 2029.
Crennen also holds multiple restricted stock unit (RSU) awards, each representing a contingent right to receive one share of common stock. These RSUs cover blocks such as 1,800 shares, 1,443 shares, 735 shares, 542 shares, 465 shares, and 125 shares, with vesting schedules that extend in tranches through 2029.
Mesa Laboratories executive Brian David Archbold reported compensation-related equity changes. On June 15, 2026, he exercised derivative awards to acquire 2,454 shares of Mesa Laboratories common stock at $104.08 per share, increasing his direct common stock holdings to 4,861 shares.
He also received a new grant of 4,328 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in stages starting on June 15, 2026. In addition, 1,780 Non Qualified Stock Options with a $226.72 exercise price reached expiration.
Following these transactions, Archbold holds 4,328 RSUs and 11,852 Non Qualified Stock Options alongside his common shares, reflecting ongoing equity-based compensation rather than open-market buying or selling.
Mesa Laboratories CFO John Sakys reported compensation-related equity changes. He exercised derivative awards to acquire 2,717 shares of common stock, bringing his direct holdings to 17,761 shares. He also received a grant of 8,416 restricted stock units, each representing one future share of common stock.
In addition, 3,951 non-qualified stock options with a $226.72 exercise price reached expiration. Sakys also reports 50 shares of common stock held indirectly as custodian for his children.
Mesa Laboratories appointed Lyndsey Crennen as Chief Accounting Officer, effective upon entry into a new Employment Agreement. She has over 20 years of accounting experience and has served in progressively senior roles at Mesa since 2018, including Corporate Controller since 2022.
Under the expected Employment Agreement, Crennen will receive a base salary of $325,000, be eligible for an annual cash bonus equal to 40% of base salary under the short-term incentive plan, and have a long-term incentive target award value of $300,000. The agreement includes customary severance and other terms, and the company states there are no related-party transactions or family relationships requiring disclosure.
Mesa Laboratories outlines its business, strategy and risks as a global provider of life sciences tools and quality-control solutions serving pharmaceutical, healthcare and medical device markets. The company operates four divisions: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions and Clinical Genomics.
Mesa highlights its lean-based "Mesa Way" operating system, focus on recurring consumables revenue and global manufacturing footprint in the U.S. and Europe. It reports a GKE acquisition for $87,187 (net of cash and liabilities) to expand sterilization indicators, and backlog of $33.6 million as of March 31, 2026 versus $43.2 million a year earlier, mainly from timing in Clinical Genomics and normalized sterilization orders.
The filing details diversified customers, with no single customer above 10% of consolidated revenue, though one Clinical Genomics customer represents about 20% of that division’s revenue. Mesa also discloses 717 employees, reliance on key talent, and extensive risk factors spanning macro conditions, international operations, supply chain, regulation, cybersecurity, climate, tariffs and a planned CEO transition effective April 2026.
Mesa Laboratories reported modest growth for its fourth quarter and full fiscal year 2026 ended March 31, 2026. Quarterly revenues were $63,724, up 2.6% year over year, with strong Sterilization and Disinfection Control growth offset by a sharp decline in Biopharmaceutical Development.
For FY26, revenues reached $249,130, a 3.4% increase, while net income improved to $6,712, or $1.21 per diluted share, compared with a prior-year loss. Non-GAAP adjusted operating income excluding unusual items rose 11.9% to $63,487, representing a 25.5% margin. Free cash flow was $39,581, allowing the company to reduce its Total Net Leverage Ratio to 2.11.
Mesa Laboratories President and CEO Siddhartha Kadia received a grant of restricted stock units that can convert into 35,236 shares of common stock. The award was recorded at a price of $0.00 per unit as a stock-based compensation grant. Each RSU represents a right to receive one share of common stock and is scheduled to vest in three equal installments, with one-third vesting on each anniversary date of the grant. Following this award, Kadia is reported as directly holding 35,236 RSUs tied to common stock.